JOZAL MOORE MD
Prescription History 1780113449
Internal Medicine in Rochester, NY
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JOZAL MOORE MD, an active Internal Medicine specialist practicing in Rochester, NY. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 123 documented patient claims. Among these therapy options, the most frequently utilized medication is Hydroxyurea, which accounts for 37 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2024)Rx (2024) | Avg Cost per FillCost / Fill | Vs. Other NY PrescribersVs. NY Avg |
|---|---|---|---|
| Hydroxyurea | 37 | $19.93▼ below NY avg | ≈ Typical |
About Hydroxyurea: This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Show more ▾ Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas). An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. In 2024, this provider wrote 37 Medicare prescriptions for Hydroxyurea, about the same volume as the typical New York prescriber of this medication (35.9). Medicare paid an average of $19.93 per fill, versus $21.65 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 47.3 30-Day Fills standardized to 30-day supplies 1,416 Days of Medication total across all patients in 2024 | |||
| Acyclovir | 31 | $8.84▼ below NY avg | ≈ Typical |
About Acyclovir: Acyclovir is used to treat infections caused by certain types of viruses. Show more ▾ It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections. A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. In 2024, this provider wrote 31 Medicare prescriptions for Acyclovir, about the same volume as the typical New York prescriber of this medication (30.3). Medicare paid an average of $8.84 per fill, versus $25.41 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 38 30-Day Fills standardized to 30-day supplies 1,140 Days of Medication total across all patients in 2024 | |||
| Imatinib Mesylate | 17 | $3,171.59 | ≈ Typical |
About Imatinib Mesylate: This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). Show more ▾ It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome). A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors. In 2024, this provider wrote 17 Medicare prescriptions for Imatinib Mesylate, about 77% of the volume of the typical New York prescriber of this medication (22.2). Medicare paid an average of $3,171.59 per fill, versus $1,831.13 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 17 30-Day Fills standardized to 30-day supplies 510 Days of Medication total across all patients in 2024 | |||
| Fluconazole | 15 | $31.53 | ▼ Less than typical |
About Fluconazole: Fluconazole is used to treat vaginal yeast infections. Show more ▾ It works by stopping the growth of common types of vaginal yeast (fungus). This medication belongs to a class of drugs called azole antifungals. Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS. In 2024, this provider wrote 15 Medicare prescriptions for Fluconazole, about 68% of the volume of the typical New York prescriber of this medication (22.2). Medicare paid an average of $31.53 per fill, versus $12.21 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 17.6 30-Day Fills standardized to 30-day supplies 526 Days of Medication total across all patients in 2024 | |||
| InqoviDecitabine/Cedazuridine | 12 | $8,318.63 | ▼ Less than typical |
About Inqovi: This medication contains 2 ingredients: decitabine and cedazuridine. Show more ▾ It is used to treat a group of blood/bone marrow disorders (myelodysplastic syndromes-MDS) in which the bone marrow does not produce enough healthy blood cells. People with MDS may have problems such as infections, anemia, and easy bleeding/bruising. Decitabine is thought to work by helping your bone marrow make normal blood cells. Decitabine also slows or stops the growth of abnormal blood cells that grow too fast and do not work properly. Cedazuridine helps decitabine work better by helping to prevent its breakdown in your body. In 2024, this provider wrote 12 Medicare prescriptions for Inqovi, about 64% of the volume of the typical New York prescriber of this medication (18.8). Medicare paid an average of $8,318.63 per fill, versus $7,677.32 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 12 30-Day Fills standardized to 30-day supplies 336 Days of Medication total across all patients in 2024 | |||
| Lenalidomide | 11 | $14,761.07 | ▼ Less than typical |
About Lenalidomide: Lenalidomide is used to treat various types of cancers. Show more ▾ It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication. A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA. In 2024, this provider wrote 11 Medicare prescriptions for Lenalidomide, about a third of the volume of the typical New York prescriber of this medication (37.8). Medicare paid an average of $14,761.07 per fill, versus $13,642.21 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 11 30-Day Fills standardized to 30-day supplies 308 Days of Medication total across all patients in 2024 | |||
About this data. The prescription history for JOZAL MOORE MD is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2024, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Internal Medicine prescribing approach at this Rochester, NY practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average among NY prescribers of the same medication and form, shown only when at least five prescribers contribute. Always confirm current medications and costs directly with the provider and your plan.
About the medication summaries. Drug use descriptions come from the CMS Medicare Part D Drug Spending Dashboard (2024), and substance definitions from Medical Subject Headings (MeSH) 2026, U.S. National Library of Medicine. They are summaries that do not contain all possible information about a medication and are not individual medical advice. Ask a health care professional about any medication and your specific health needs.
